EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Biomarkers of Fibrosis in Patients with COVID-19 One Year After Hospital Discharge: A Prospective Cohort Study

Alba Mulet iD, Julia Tarrasó iD, Enrique Rodríguez-Borja, Juan A Carbonell-Asins, Amaia Lope-Martínez, Arancha Martí-Martinez, Rosa Murria, Belén Safont, Estrella Fernandez-Fabrellas, José A Ros, Juan A Rodriguez-Portal, Ada L Andreu und 2 weitere

American Journal of Respiratory Cell and Molecular Biology · 2023

DOI: 10.1165/rcmb.2022-0474oc ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2023. Verfasst von Alba Mulet und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Department, Hospital Clínico, and. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pneumology Foundation of Comunidad Valenciana, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Beyond the acute infection of coronavirus disease (COVID-19), concern has arisen about long-term effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of our study was to analyze if there is any biomarker of fibrogenesis in patients with COVID-19 pneumonia capable of predicting post-COVID-19 pulmonary sequelae. We conducted a multicenter, prospective, observational cohort study of patients admitted to a hospital with bilateral COVID-19 pneumonia. We classified patients into two groups according to severity, and blood sampling to measure matrix metalloproteinase 1 (MMP-1), MMP-7, periostin, and VEGF and respiratory function tests and high-resolution computed tomography were performed at 2 and 12 months after hospital discharge. A total of 135 patients were evaluated at 12 months. Their median age was 61 (interquartile range, 19) years, and 58.5% were men. We found between-group differences in age, radiological involvement, length of hospital stay, and inflammatory laboratory parameters. Differences were found between 2 and 12 months in all functional tests, including improvements in predicted forced vital capacity (98.0% vs. 103.9%; P = 0.001) and Dl CO <80% (60.9% vs. 39.7%; P = 0.001). At 12 months, 63% of patients had complete high-resolution computed tomography resolution, but fibrotic changes persisted in 29.4%. Biomarker analysis demonstrated differences at 2 months in periostin (0.8893 vs. 1.437 ng/ml; P < 0.001) and MMP-7 (8.7249 vs. 15.2181 ng/ml; P < 0.001). No differences were found at 12 months. In multivariable analysis, only 2-month periostin was associated with 12-month fibrotic changes (odds ratio, 1.0013; 95% confidence interval, 1.0006–1.00231; P = 0.003) and 12-month Dl CO impairment (odds ratio, 1.0006; 95% confidence interval, 1.0000–1.0013; P = 0.047). Our data suggest that early periostin postdischarge could predict the presence of fibrotic pulmonary changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19MaleHumansMiddle AgedFemaleProspective StudiesMatrix Metalloproteinase 7AftercarePatient DischargeCohort StudiesBiomarkersFibrosisHospitals

Stichwörter der Autor:innen

COVID-19fibrosis biomarkerspulmonary fibrosispulmonary sequelae

Substanzen

Matrix Metalloproteinase 7Biomarkers

Autor:innen und Institutionen

  • Pulmonary Department, Hospital Clínico, and.
  • Laboratory of Biochemistry and Molecular Pathology, Hospital Clínico de Valencia, Valencia, Spain.
  • Bioinformatics and Biostatistics Unit, INCLIVA, University of Valencia, Valencia, Spain.
  • Pulmonary Department, Hospital General, Valencia, Spain.
  • Pulmonary Department, Hospital Virgen de la Arrixaca, Murcia, Spain.
  • Pulmonary Department, Hospital Virgen del Rocío, Sevilla, Spain.

ORCID-Profile: Alba Mulet, Julia Tarrasó, Jaime Signes-Costa

Förderung

  • Pneumology Foundation of Comunidad Valenciana
  • Instituto de Salud Carlos III

Zitieren

APA

Mulet, A., Tarrasó, J., Rodríguez-Borja, E., Carbonell-Asins, J. A., Lope-Martínez, A., Martí-Martinez, A., Murria, R., Safont, B., Fernandez-Fabrellas, E., Ros, J. A., Rodriguez-Portal, J. A., Andreu, A. L., Soriano, J. B., & Signes-Costa, J. (2023). Biomarkers of Fibrosis in Patients with COVID-19 One Year After Hospital Discharge: A Prospective Cohort Study. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2022-0474oc

Vancouver

Mulet A, Tarrasó J, Rodríguez-Borja E, Carbonell-Asins JA, Lope-Martínez A, Martí-Martinez A, et al. Biomarkers of Fibrosis in Patients with COVID-19 One Year After Hospital Discharge: A Prospective Cohort Study. American Journal of Respiratory Cell and Molecular Biology. 2023. doi:10.1165/rcmb.2022-0474oc

BibTeX
@article{Mulet2023,
  author = {Mulet, Alba and Tarrasó, Julia and Rodríguez-Borja, Enrique and Carbonell-Asins, Juan A and Lope-Martínez, Amaia and Martí-Martinez, Arancha and Murria, Rosa and Safont, Belén and Fernandez-Fabrellas, Estrella and Ros, José A and Rodriguez-Portal, Juan A and Andreu, Ada L and Soriano, Joan B and Signes-Costa, Jaime},
  title = {Biomarkers of Fibrosis in Patients with COVID-19 One Year After Hospital Discharge: A Prospective Cohort Study},
  journal = {American Journal of Respiratory Cell and Molecular Biology},
  year = {2023},
  doi = {10.1165/rcmb.2022-0474oc}
}
Kostenlos starten →